Dupilumab exposure and herpesvirus infection risk in atopic dermatitis: A claims‐based cohort study
The data that support the findings of this study were obtained under a contract with IQVIA Solutions Japan G.K. and are not publicly available. Data may be available from IQVIA Solutions Japan G.K. subject to applicable permissions, contractual restrictions, and privacy or ethical considerations.
Authors
- Takahiro Itaya (ORCID: https://orcid.org/0000-0002-0560-8686)
- Yusuke Ogawa (ORCID: https://orcid.org/0000-0001-9256-5102)
- K. Goto (ORCID: https://orcid.org/0000-0003-2370-015X)
- Kenji Kabashima (ORCID: https://orcid.org/0000-0002-0773-0554)
- Shinji Okabayashi (ORCID: https://orcid.org/0000-0003-2683-9018)
- Yosuke Yamamoto (ORCID: https://orcid.org/0000-0003-1104-2612)
- Masaaki Isshiki
- Yoshie Yamada
Institutions
- Kyoto University (JP)
- IQVIA (United Kingdom) (GB)
- IQ Solutions (US)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2026-09-17
- DOI
- https://doi.org/10.1111/jdv.70739
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Torii Pharmaceutical
- LEO Pharma